APEX Study: Effects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients With Cardiac Syndrome X
Information source: University of Dundee
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Syndrome X
Intervention: allopurinol (Drug); placebo (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: University of Dundee Official(s) and/or principal investigator(s):
Chim Lang, Principal Investigator, Affiliation: University of Dundee
Overall contact:
tiong lim, Phone: 01382632180, Email: t.k.lim@dundee.ac.uk
Summary
Morbidity of patients with cardiac syndrome X (typical anginal-like chest pain and normal
coronary arteriograms) is high with continuing episodes of chest pain and frequent hospital
readmissions. Management of this syndrome represents a major challenge to the treating
physician. Evidence for the important role of endothelial dysfunction and oxidative stress in
the pathogenesis of cardiac syndrome X has been recently strengthened by the finding that
basal superoxide production predicts future cardiovascular events in this patient group. We
have recently shown that high-dose allopurinol abolishes vascular oxidative stress and
improves endothelial function in patients with chronic heart failure, which makes allopurinol
a prime candidate to reduce oxidative stress in syndrome X. The hypothesis to be tested in
this study is whether allopurinol offers dual benefits of improving vascular function and
reducing myocardial ischaemia in patients with cardiac syndrome X. This study may discover a
novel way to improve endothelial function and anginal symptoms which are often debilitating
in these patients.
Clinical Details
Official title: APEX Study: Effects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients With Cardiac Syndrome X
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Efficacy Study
Primary outcome: The primary objective of this study is to investigate the effects of allopurinol on coronary and peripheral microvascular and endothelial function in patients with cardiac syndrome X
Secondary outcome: The secondary objectives of this study are to assess the effects of allopurinol on chest pain incidence, maximal ST-segment depression and Duke's score
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Typical history of angina
- Positive exercise treadmill test and normal coronary angiogram
Exclusion Criteria:
- Significant valvular heart disease or left ventricular hypertrophy
- Age <18 years
Locations and Contacts
tiong lim, Phone: 01382632180, Email: t.k.lim@dundee.ac.uk
University of Dundee, Dundee dd1 3sy, United Kingdom; Recruiting
Tiong K Lim, MBBS, Phone: 01382 644972, Email: t.k.lim@dundee.ac.uk
Chim C Lang, MD, Phone: 01382 644972, Email: c.c.lang@dundee.ac.uk
Chim C Lang, MD, Principal Investigator
Additional Information
Starting date: June 2008
Ending date: December 2010
Last updated: July 8, 2008
|
